Literature DB >> 11839421

Therapeutic administration of nitric oxide synthase inhibitors reverses hyperalgesia but not inflammation in a rat model of polyarthritis.

Laura S Tedesco1, John Fuseler, Matthew Grisham, Robert Wolf, Sandra C Roerig.   

Abstract

Nitric oxide (NO) has been postulated to play a role in pain as well as in inflammation. In the present studies, the effects of NO synthase (NOS) inhibitors on both pain and inflammation were examined in a rat model of polyarthritis. Female Lewis rats were injected intraperitoneally (i.p.) with peptidoglycan/polysaccharide (PG/PS) or saline to induce arthritis. Hind paw volume, response latency to thermal nociceptive stimulus and mechanical threshold were measured daily for the next 35 days. Paw inflammation, thermal hyperalgesia and mechanical allodynia developed in all rats that received PG/PS compared to saline. On day 19 (chronic inflammation phase), rats were given either N(G)-nitro-L-arginine methyl ester (L-NAME, non-selective NOS inhibitor, 100 mg/l), L-N (6)-(1-iminoethyl) lysine (L-NIL, selective inducible NOS inhibitor, 10 mg/l) or no drug in drinking water. By day 21, L-NAME treatment reversed the thermal hyperalgesia completely and this effect remained until day 35. Similarly, L-NIL treatment reversed thermal hyperalgesia from days 24 to 34. Neither treatment affected mechanical allodynia. Paw volume was not different between PG/PS treated and PG/PS plus L-NAME treated rats. However, the PG/PS plus L-NIL treatment produced an increase in paw volume greater than did PG/PS alone. Other rats were treated with PG/PS plus the antiinflammatory agent indomethacin (days 19-35). Indomethacin treatment reversed all the measured parameters, although the reversal of mechanical allodynia was only partial. These results suggest that NO is involved in thermal, but not mechanical sensory pathways and that the selective inhibition of inducible NOS activity exacerbates established inflammation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839421     DOI: 10.1016/S0304-3959(01)00402-X

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  7 in total

1.  Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats.

Authors:  T Croci; E Zarini
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

2.  HgCl2 challenge in Brown Norway rats lead to dermatitis instead of arthritis.

Authors:  K Schümann; A Lebeau; T Ettle; O Adam
Journal:  Rheumatol Int       Date:  2005-07-16       Impact factor: 2.631

3.  Strigolactones: a plant phytohormone as novel anti-inflammatory agents.

Authors:  Jun-Xia Zheng; Yu-Shui Han; Jin-Cai Wang; Hui Yang; Hao Kong; Kang-Jia Liu; Si-Yu Chen; Yi-Rui Chen; Yi-Qun Chang; Wei-Min Chen; Jia-Liang Guo; Ping-Hua Sun
Journal:  Medchemcomm       Date:  2017-12-05       Impact factor: 3.597

4.  Mycobacteria attenuate nociceptive responses by formyl peptide receptor triggered opioid peptide release from neutrophils.

Authors:  Heike L Rittner; Dagmar Hackel; Philipp Voigt; Shaaban Mousa; Andrea Stolz; Dominika Labuz; Michael Schäfer; Michael Schaefer; Christoph Stein; Alexander Brack
Journal:  PLoS Pathog       Date:  2009-04-03       Impact factor: 6.823

5.  Toll like receptor (TLR)-4 as a regulator of peripheral endogenous opioid-mediated analgesia in inflammation.

Authors:  Reine-Solange Sauer; Dagmar Hackel; Laura Morschel; Henrike Sahlbach; Ying Wang; Shaaban A Mousa; Norbert Roewer; Alexander Brack; Heike L Rittner
Journal:  Mol Pain       Date:  2014-02-06       Impact factor: 3.395

6.  Molecular hydrogen attenuates neuropathic pain in mice.

Authors:  Masanori Kawaguchi; Yasushi Satoh; Yukiko Otsubo; Tomiei Kazama
Journal:  PLoS One       Date:  2014-06-18       Impact factor: 3.240

7.  Thermal camera as a pain monitor.

Authors:  Varlik K Erel; Heval Selman Özkan
Journal:  J Pain Res       Date:  2017-12-14       Impact factor: 3.133

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.